Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.03 USD | +1.77% | +6.05% | +9.02% |
05-09 | NeuroBo Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-08 | Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target | MT |
Business Summary
Number of employees: 8
Managers
Managers | Title | Age | Since |
---|---|---|---|
Hyung-Heon Kim
CEO | Chief Executive Officer | 47 | 08/07/21 |
Director of Finance/CFO | 66 | 26/10/23 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
D. Strickland
BRD | Director/Board Member | 77 | 26/01/22 |
Andrew Koven
CHM | Chairman | 66 | 08/07/21 |
Mark Glickman
BRD | Director/Board Member | 58 | 10/05/23 |
Michael Salsbury
BRD | Director/Board Member | 74 | 30/12/19 |
Jason Groves
BRD | Director/Board Member | 52 | 30/12/19 |
James Tursi
BRD | Director/Board Member | 59 | 10-31 |
Hyung-Heon Kim
CEO | Chief Executive Officer | 47 | 08/07/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 4,906,002 | 1,880,689 ( 38.33 %) | 0 | 38.33 % |
Company contact information
NeuroBo Pharmaceuticals, Inc.
545 Concord Avenue Suite 210
02138, Cambridge
+
http://www.neurobopharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.02% | 19.43M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- NRBO Stock
- Company NeuroBo Pharmaceuticals, Inc.